6-mercaptopurine influences TPMT gene transcription in a TPMT gene promoter variable number of tandem repeats-dependent manner

Pharmacogenomics

Volumn 13, Issue 3, 2012, Pages 283-295

  Kotur, Nikola ^a   Stankovic, Biljana ^a   Kassela, Katerina ^a   Georgitsi, Marianthi ^a   Vicha, Anna ^a   Leontari, Iliana ^a   Dokmanovic, Lidija ^a   Janic, Dragana ^a   Krstovski, Nada ^a   Klaassen, Kristel ^a   Radmilovic, Milena ^a   Stojiljkovic, Maja ^a   Nikcevic, Gordana ^a   Simeonidis, Argiris ^a   Sivolapenko, Gregory ^a   Pavlovic, Sonja ^a   Patrinos, George P ^a   Zukic, Branka ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

6 mercaptopurine; pharmacogenomics; reporter assay; TPMT; TPMT gene promoter; VNTR

Indexed keywords

MERCAPTOPURINE; NUCLEAR PROTEIN; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG DOSE REDUCTION; GEL MOBILITY SHIFT ASSAY; GENE; GENETIC MARKER; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; LEUKOPENIA; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PREDICTION; PROMOTER REGION; PROTEIN BINDING; SCHOOL CHILD; SOUTHWESTERN BLOTTING; TPMT GENE; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

6-MERCAPTOPURINE; ALLELES; GENOTYPE; HUMANS; K562 CELLS; METHYLTRANSFERASES; MINISATELLITE REPEATS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 84856747776     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.153     Document Type: Article

References (63)

1. Coulthard S, Hogarth L. The thiopurines: an update. Invest. New Drugs 23(6), 523-532 (2005). (Pubitemid 43162471)
2. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43(4), 329-339 (1992).
3. Tay BS, Lilley RM, Murray AW, Atkinson MR. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem. Pharmacol. 18(4), 936-938 (1969).
4. Maybaum J, Mandel HG. Differential chromatid damage induced by 6-thioguanine in CHO cells. Exp. Cell. Res. 135(2), 465-468 (1981). (Pubitemid 12220377)
5. Maybaum J, Mandel HG. Unilateral chromatid damage: a new basis for 6-thioguanine cytotoxicity. Cancer Res. 43(8), 3852-3856 (1983). (Pubitemid 13077716)
6. Christie NT, Drake S, Meyn RE, Nelson JA. 6-Thioguanine-induced DNA damage as a determinant of cytotoxicity in cultured Chinese hamster ovary cells. Cancer Res. 44(9), 3665-3671 (1984). (Pubitemid 14041572)
7. Pan BF, Nelson JA. Characterization of the DNA damage in 6-thioguanine-treated cells. Biochem. Pharmacol. 40(5), 1063-1069 (1990). (Pubitemid 20259712)
8. Bodell WJ. Molecular dosimetry of sister chromatid exchange induction in 9L cells treated with 6-thioguanine. Mutagenesis 6(3), 175-177 (1991).
9. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin. Pharmacol. Ther. 41(1), 18-25 (1987). (Pubitemid 17008125)
10. Griffiths AM. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary. Inflamm. Bowel Dis. 9(6), 389-391 (2003). (Pubitemid 37461451)
11. Colombel JF, Ferrari N, Debuysere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118(6), 1025-1030 (2000). (Pubitemid 30346978)
12. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25(11), 1629-1638 (2006).
13. Landy J, Bhuva N, Marinaki A, Mawdsley J. Novel thiopurine methyltransferase variant TPMT*28 results in a misdiagnosis of TPMT deficiency. Inflamm. Bowel Dis. 17(6), 1441-1442 (2011).
14. Appell ML, Wennerstrand P, Peterson C, Hertervig E, Martensson LG. Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene. Pharmacogenet. Genomics 20(11), 700-707 (2010).
15. Krynetski EY, Fessing MY, Yates CR, Sun D, Schuetz JD, Evans WE. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharm. Res. 14(12), 1672-1678 (1997). (Pubitemid 28062909)
16. Fessing MY, Krynetski EY, Zambetti GP, Evans WE. Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. Eur. J. Biochem. 256(3), 510-517 (1998). (Pubitemid 28440416)
17. Spire-Vayron De La Moureyre C, Debuysere H, Fazio F et al. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 9(2), 189-198 (1999). (Pubitemid 29359001)
18. Yan L, Zhang S, Eiff B et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin. Pharmacol. Ther. 68(2), 210-219 (2000). (Pubitemid 30659176)
19. Alves S, Amorim A, Ferreira F, Prata MJ. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin. Pharmacol. Ther. 70(2), 165-174 (2001). (Pubitemid 32777769)
20. Zukic B, Radmilovic M, Stojiljkovic M et al. Functional analysis of the role of the TPMT gene promoter VNTR polymorphism in TPMT gene transcription. Pharmacogenomics 11(4), 547-557 (2010).
21. Spire-Vayron De La Moureyre C, Debuysere H, Mastain B et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J. Pharmacol. 125(4), 879-887 (1998). (Pubitemid 28482633)
22. Marinaki AM, Arenas M, Khan ZH et al. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 13(2), 97-105 (2003). (Pubitemid 36259589)
23. Fronkova E, Mejstrikova E, Avigad S et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia 22(5), 989-997 (2008). (Pubitemid 351689881)
24. Papachatzopoulou A, Kaimakis P, Pourfarzad F et al. Increased gamma-globin gene expression in beta-thalassemia intermedia patients correlates with a mutation in 3'HS1. Am. J. Hematol. 82(11), 1005-1009 (2007). (Pubitemid 350017431)
25. Michael N, Spector D, Mavromara-Nazos P, Kristie TM, Roizman B. The DNA-binding properties of the major regulatory protein alpha 4 of herpes simplex viruses. Science 239(4847), 1531-1534 (1988).
26. Pavlovic S, Mitrovic T, Nikcevic G et al. The rat beta (b miny)-globin promoter: nuclear protein factors and erythroid-specific induction of transcription. Cell Mol. Life Sci. 56(9-10), 871-881 (1999).
27. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. USA 92(4), 949-953 (1995).
28. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl Acad. Sci. USA 94(12), 6444-6449 (1997). (Pubitemid 27270704)
29. Tai HL, Fessing MY, Bonten EJ et al. Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics 9(5), 641-650 (1999).
30. Loennechen T, Yates CR, Fessing MY, Relling MV, Krynetski EY, Evans WE. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin. Pharmacol. Ther. 64(1), 46-51 (1998). (Pubitemid 28377329)
31. Booth RA, Ansari MT, Loit E et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann. Intern. Med. 154(12), 814-823 (2011).
32. Arenas M, Duley JA, Ansari A et al. Genetic determinants of the pre-and post-azathioprine therapy thiopurine methyltransferase activity phenotype. Nucleosides Nucleotides Nucleic Acids 23(8-9), 1403-1405 (2004). (Pubitemid 39625933)
33. Spire-Vayron De La Moureyre C, Debuysere H, Sabbagh N et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum. Mutat. 12(3), 177-185 (1998). (Pubitemid 28384589)
34. Georgitsi M, Zukic B, Pavlovic S, Patrinos GP. Transcriptional regulation and pharmacogenomics. Pharmacogenomics 12(5), 655-673 (2011).
35. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333(18), 1171-1175 (1995).
36. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95(14), 8170-8174 (1998). (Pubitemid 28326085)
37. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, Mcleod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007). (Pubitemid 47394168)
38. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5́-terminal regulatory region of the human gene for thymidylate synthase. Cell. Struct. Funct. 20(3), 191-197 (1995).
39. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001). (Pubitemid 33757985)
40. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359(9311), 1033-1034 (2002). (Pubitemid 34286543)
41. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008 (1999).
42. Adamson PC, Balis FM, Hawkins ME, Murphy RF, Poplack DG. Desulfuration of 6-mercaptopurine. The basis for the paradoxical cytotoxicity of thiopurines in cultured human leukemic cells. Biochem. Pharmacol. 46(9), 1627-1636 (1993). (Pubitemid 23338498)
43. Wansa KD, Muscat GE. TRAP220 is modulated by the antineoplastic agent 6-mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors. J. Mol. Endocrinol. 34(3), 835-848 (2005). (Pubitemid 40903605)
44. Galleguillos D, Vecchiola A, Fuentealba JA et al. PIASgamma represses the transcriptional activation induced by the nuclear receptor Nurr1. J. Biol. Chem. 279(3), 2005-2011 (2004). (Pubitemid 38084471)
45. Tempe D, Piechaczyk M, Bossis G. SUMO under stress. Biochem. Soc. Trans. 36(Pt 5), 874-878 (2008).
46. Siatecka M, Xue L, Bieker JJ. Sumoylation of EKLF promotes transcriptional repression and is involved in inhibition of megakaryopoiesis. Mol. Cell Biol. 27(24), 8547-8560 (2007).
47. Wilkerson DC, Wolfe SA, Grimes SR. H1t/GC-box and H1t/TE1 element are essential for promoter activity of the testis-specific histone H1t gene. Biol. Reprod. 67(4), 1157-1164 (2002).
48. Hernandez EM, Johnson A, Notario V, Chen A, Richert JR. AUA as a translation initiation site in vitro for the human transcription factor Sp3. J. Biochem. Mol. Biol. 35(3), 273-282 (2002). (Pubitemid 34655871)
49. Liang Y, Robinson DF, Dennig J, Suske G, Fahl WE. Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors. J. Biol. Chem. 271(20), 11792-11797 (1996). (Pubitemid 26157248)
50. Li L, He S, Sun JM, Davie JR. Gene regulation by Sp1 and Sp3. Biochem. Cell Biol. 82(4), 460-471 (2004). (Pubitemid 39286961)
51. Valin A, Gill G. Regulation of the dual-function transcription factor Sp3 by SUMO. Biochem. Soc. Trans. 35(Pt 6), 1393-1396 (2007).
52. Ross S, Best JL, Zon LI, Gill G. SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol. Cell 10(4), 831-842 (2002). (Pubitemid 35335638)
53. Sapetschnig A, Rischitor G, Braun H et al. Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J. 21(19), 5206-5215 (2002).
54. Spengler ML, Brattain MG. Sumoylation inhibits cleavage of Sp1 N-terminal negative regulatory domain and inhibits Sp1-dependent transcription. J. Biol. Chem. 281(9), 5567-5574 (2006). (Pubitemid 43847653)
55. Borg J, Patrinos GP, Felice AE, Philipsen S. Erythroid phenotypes associated with KLF1 mutations. Haematologica 96(5), 635-638 (2011).
56. Perkins AC, Sharpe AH, Orkin SH. Lethal beta-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature 375(6529), 318-322 (1995).
57. Funnell AP, Maloney CA, Thompson LJ et al. Erythroid Kruppel-like factor directly activates the basic Kruppel-like factor gene in erythroid cells. Mol. Cell. Biol. 27(7), 2777-2790 (2007). (Pubitemid 46581365)
58. Chen X, Bieker JJ. Unanticipated repression function linked to erythroid Kruppel-like factor. Mol. Cell. Biol. 21(9), 3118-3125 (2001). (Pubitemid 32298378)
59. Chen X, Bieker JJ. Stage-specific repression by the EKLF transcriptional activator. Mol. Cell. Biol. 24(23), 10416-10424 (2004). (Pubitemid 39507878)
60. Borg J, Papadopoulos P, Georgitsi M et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat. Genet. 42(9), 801-805 (2010).
61. Giardine B, Borg J, Higgs DR et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat. Genet. 43(4), 295-301 (2011).
62. Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 107(2), 843-844 (2006). (Pubitemid 43076417)
63. Dokmanovic L, Urosevic J, Janic D et al. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia. Ther. Drug Monit. 28(6), 800-806 (2006). (Pubitemid 44967661)